

(19) United States

(12) Patent Application Publication (10) Pub. No.: US 2021/0317212 A1 Ng et al.

Oct. 14, 2021 (43) **Pub. Date:**

(54) **BISPECIFIC ASYMMETRIC HETERODIMERS COMPRISING ANTI-CD3 CONSTRUCTS**

(71) Applicant: **ZYMEWORKS INC.**, Vancouver (CA)

(72) Inventors: Gordon Yiu Kon Ng, Vancouver (CA); Surjit Bhimarao Dixit, Richmond (CA); Thomas Spreter von Kreudenstein, Vancouver (CA); Nina E. Weisser, Delta (CA)

(21) Appl. No.: 17/207,526

(22) Filed: Mar. 19, 2021

Related U.S. Application Data

- (63) Continuation of application No. 16/256,824, filed on Jan. 24, 2019, now abandoned, which is a continuation of application No. 13/941,449, filed on Jul. 13, 2013, now abandoned.
- Provisional application No. 61/845,948, filed on Jul. 12, 2013, provisional application No. 61/671,640, filed on Jul. 13, 2012.

Publication Classification

(51) Int. Cl. C07K 16/28 (2006.01)C07K 16/32 (2006.01)

(52) U.S. Cl.

CPC C07K 16/2809 (2013.01); C07K 2317/524 (2013.01); C07K 16/2887 (2013.01); C07K 16/32 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/526 (2013.01); C07K 2317/528 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2317/71 (2013.01); C07K 2317/72 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/74 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/31 (2013.01); C07K 2317/52 (2013.01); C07K 16/2803 (2013.01)

(57)ABSTRACT

Disclosed herein are isolated multi-specific heteromultimer constructs that bind to CD3 expressed on T-cells and to an antigen expressed on B-cells. The multi-specific heteromultimer constructs are capable of bridging T- and B-cells and mediating killing of B-cells. The multi-specific heteromultimer constructs are based on a heterodimeric Fc scaffold or on a segmented albumin scaffold. Also disclosed herein are multi-specific heteromultimer constructs that bind to HER2 and HER3.

Specification includes a Sequence Listing.